Highlights:
- Entwickelt, um die Abläufe bei klinischen Studien für Sponsoren, Studienzentren und Studienteams zu optimieren
- Read more »
Fortrea Lança Fortrea Intelligent Technology™ para Ajudar Patrocinadores e Sites a Executar Testes Mais Inteligentes e Integrados
Destaques:
- Criada para transformar as operações de ensaios clínicos de patrocinadores, locais e equipes de estudo
- Read more »
Fortrea dévoile Fortrea Intelligent Technology™ : une technologie destinée à permettre aux investigateurs et aux centres d’essais cliniques de mener des essais plus intelligents et mieux intégrés
Points clés :
- Une solution conçue pour révolutionner les processus liés aux essais cliniques en collaboration avec les [...] Read more »
Fortrea Unveils Fortrea Intelligent Technology™ to Help Sponsors and Sites Run Smarter, More Integrated Trials
Highlights:
- Designed to transform clinical trial operations for sponsors, sites and study teams
- Persona driven, AI-powered solutions automate workflows and streamline oversight to help [...] Read more »
Nucleus Brings Genetic Optimization to India and the Middle East Through Leading IVF Networks
NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Nucleus [...] Read more »
Curia renforce ses capacités de production à Glasgow et consolide sa plateforme de développement de lignées cellulaires
ALBANY, New York, 19 mars 2026 (GLOBE NEWSWIRE) -- Curia, acteur majeur de la recherche, du développement et de la fabrication sous contrat (CDMO), annonce ce jour la progression de l’extension de son site de production [...] Read more »
Curia erweitert seine Produktionskapazitäten in Glasgow und verbessert seine Plattform zur Entwicklung von Zelllinien
ALBANY, New York, March 19, 2026 (GLOBE NEWSWIRE) -- Curia, ein führendes Auftragsforschungs-, Entwicklungs- und Produktionsunternehmen (CDMO), gab heute Fortschritte bei der Erweiterung seiner Anlage für sterile Arzneimittel in [...] Read more »
Curia Expande Capacidade de Fabricação de Glasgow e Aprimora Plataforma de Desenvolvimento de Linhagem Celular
ALBANY, N.Y., March 19, 2026 (GLOBE NEWSWIRE) -- A Curia, uma organização líder em pesquisa, desenvolvimento e fabricação por contrato (CDMO), anunciou hoje o progresso na expansão da sua unidade [...] Read more »
Curia Expands Glasgow Manufacturing Capacity and Enhances Cell Line Development Platform
ALBANY, N.Y., March 19, 2026 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization (CDMO), today announced progress on the expansion at its Glasgow, UK sterile drug product facility [...] Read more »
Fortrea erweitert Führungsteam und ernennt Oren Cohen zum Chief Medical Officer und Scott Dove zum President of Clinical Pharmacology Services
DURHAM, North Carolina, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Read more »
Fortrea Expande Equipe Executiva, Nomeia Oren Cohen como Diretor Médico e Scott Dove como Presidente dos Serviços de Farmacologia Clínica
DURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Read more »
Fortrea renforce son équipe de direction en nommant Oren Cohen au poste de directeur médical et Scott Dove à celui de président des services de pharmacologie clinique
DURHAM, Caroline du Nord, 17 févr. 2026 (GLOBE NEWSWIRE) -- Read more »
Fortrea Expands Executive Team, Appointing Oren Cohen as Chief Medical Officer and Scott Dove as President of Clinical Pharmacology Services
DURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fortrea [...] Read more »
Fortrea Announces Date for Fourth Quarter and Full Year 2025 Financial Results and Conference Call
DURHAM, N.C., Jan. 29, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full [...] Read more »
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
- REC–4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)
- After 12 weeks [...] Read more »